Après Venture

Transforming Clinical Research – Insights from Rauno Oja, CEO of EGeen International CorporationIn this episode, Rauno Oja, CEO of EGeen International Corporation, shares his distinctive perspective on the pharmaceutical and clinical research industry. With a background in business administration rather than medicine, Rauno entered the sector immediately after graduation and has since built one of Europe’s fastest-growing contract research organizations (CROs).Rauno discusses the persistent inefficiencies that frustrate him most in clinical trials, the limitations of technology when applied without clear strategy, and why AI alone cannot solve the industry’s challenges. He explains that true acceleration comes from direction first, tools second.Key topics include:EGeen’s evolution from an Estonian genome initiative to a full-service European CRO offering feasibility, site selection, regulatory support, patient recruitment, monitoring, project management, data management, biostatistics, and medical writingThe strategic advantage of maintaining on-site monitoring and building genuine investigator relationships in an increasingly remote industryHow early, collaborative feasibility and mock protocol exercises with sites prevent costly delays and amendmentsProven success in outperforming larger competitors in patient enrollment speed and volumeA balanced view on AI and digital tools: powerful enablers when guided by experience and clear objectivesRauno demonstrates that diverse leadership backgrounds, proactive site partnership, and disciplined use of technology can deliver faster, higher-quality clinical trials without compromising standards.Ideal for clinical operations leaders, sponsor teams, investigators, and anyone seeking practical ways to improve trial efficiency and outcomes.Tags: pharmaceutical, clinical research, CRO, patient recruitment, site engagement, trial efficiency, AI in clinical trials, Rauno Oja, EGeen International Corporation, clinical operations, feasibility studies, monitoring, biotech

Summary In this episode of the Après Venture Podcast, host Finith Jernigan sits down with Marc Teitelbaum, co-founder of Prognostic Optimization Group (POG AI).Marc shares his unconventional path from EMT and premed to biotech consulting, a PhD in regenerative medicine, drug development startups, and ultimately founding POG AI after a frustrating doctor’s visit wait time.He explains how POG AI uses intelligent patient triage and chat-based intake to create comprehensive SOAP notes, reduce physician burnout, cut wait times, and empower patients with centralized health records and longitudinal insights.Marc discusses current seed fundraising ($1.5M target), plans for Epic/Athena health integration, specialty-specific customization (e.g., ADHD), and the broader vision of making patients the quarterback of their own healthcare.A candid conversation on AI in healthcare, physician pain points, patient experience, and building a patient-centered health platform in today’s fragmented system.TakeawaysHealthcare data is often not aggregated across different specialists.Patients lack a comprehensive view of their health history.The inefficiency of the healthcare marketplace is a significant issue.HIPAA privacy regulations create barriers to data sharing.Personal experiences can drive innovation in healthcare.Long wait times for simple procedures frustrate patients.There are both flaws and positive aspects in the healthcare system.Stakeholders in healthcare complicate the efficiency of services.Innovative solutions are needed to improve patient experiences.The conversation highlights the importance of data in healthcare.Keywords healthcare, data aggregation, patient experience, innovation, HIPAA, healthcare system flaws

This episode of the Après Venture Podcast delves into the intricacies of chemical reactions, focusing on selectivity and the challenges faced in chemical synthesis. The discussion highlights innovative approaches in chemical research, including the use of deuterated solvents and NMR techniques to achieve better outcomes in reactions. The conversation also touches on future directions in the field of chemistry, emphasizing the importance of overcoming obstacles to enhance research and development.TakeawaysThe importance of selectivity in chemical reactions.Challenges often arise in chemical synthesis processes.Innovative techniques can lead to better results in chemistry.Deuterated solvents play a crucial role in NMR analysis.Understanding the reaction mechanism is key to troubleshooting.Collaboration and communication are vital in research settings.Continuous learning is essential for chemists.Future research should focus on overcoming existing challenges.The role of oxidants in chemical reactions is significant.Innovations in chemistry can lead to groundbreaking discoveries.Keywordschemical reactions, selectivity, synthesis, innovations, research, chemistry, NMR, oxidants, deuterated solvent, functionalization

In this episode of the podcast, we dive deep into the innovative world of Single Time Microneedles with CEO Jasdeep Singh. As healthcare faces numerous challenges, from patient compliance to the complexities of vaccine distribution, this technology emerges as a game changer. Join us as we explore how microneedles are set to transform community health and the pharmaceutical landscape.

What if we could watch a human cell in real time—without dyes, without fixation, without killing it—every 4 minutes for days? That’s exactly what founder Parmita Mishra is building at Precigenetics. In this episode of the Biocatalyst AI Podcast, Parmita sits down with host Finith Jernigan to unpack: How a near-fatal allergy attack in her freshman dorm at Penn forced her to pivot from wet-lab biology to computational biology—from a hospital bed in India Why hardware, not software, is the final frontier holding back biology.

The conversation focuses on the commitment to improving healthcare access in Africa, particularly through the manufacturing of monoclonal antibodies. The speaker emphasizes the importance of leveraging expertise gained in the West to benefit African patients and highlights the upcoming capabilities in producing essential medicines on the continent.

In this episode of the Apres Venture Podcast Presented by Finith Capital, host Finith Jernigan chats with Dr. Jamie Rice, Head of Discovery Biology at Covent Therapeutics. Dr. Rice shares his journey from running a construction business to earning a PhD in immunology, working on cutting-edge immuno-oncology at Harvard, and now leading autoimmune disease research. They dive into the shift from broad immunosuppressants to precision immunology, the potential of immune reset therapies, and the emerging role of peptides as game-changing, cost-effective drugs. Dr. Rice also discusses leveraging AI and advanced screening to accelerate drug discovery and the importance of balancing speed and process in biotech innovation.

Why am I starting a podcast?